According to Felix Biotechnology, Yale University researchers have initiated a Phase 1/2 trial of Felix's YPT-01 nebulized phage therapy for the treatment of chronic P. aeruginosa infections in cystic fibrosis patients. YPT-01 was initially formulated at Yale and licensed to Felix, a start-up founded by Yale Faculty. Felix recently signed a deal with TFF … [Read more...] about Phase 1/2 trial of inhaled phage therapy for the treatment of P. aeruginosa infections in CF patients gets underway
Medical
Insmed initiates Phase 3b clinical trial of Arikayce inhalation suspension for the treatment of NTM caused by MAC
Insmed announced that the first patient has been dosed in a Phase 3b trial of its Arikayce amikacin liposome inhalation suspension in patients with nontuberculous mycobacterial (NTM) lung infections caused by Mycobacterium avium complex (MAC). Arikayce is delivered via the PARI Lamira nebulizer system. The FDA approved Arikayce for the treatment of NTM lung … [Read more...] about Insmed initiates Phase 3b clinical trial of Arikayce inhalation suspension for the treatment of NTM caused by MAC
Arcturus Therapeutics to develop inhaled CFTR mRNA therapy for CF
California-based Arcturus Therapeutics announced that it will develop its ARCT-032 aerosolized CFTR mRNA formulation for the treatment of cystic fibrosis. According to Arcturus, preclinical studies of ARCT-032, which is based on the company's LUNAR (lipid-enabled and unlocked nucleomonomer agent modified RNA) technology, have demonstrated that the inhaled therapy has … [Read more...] about Arcturus Therapeutics to develop inhaled CFTR mRNA therapy for CF
Polyphor to initiate Phase 1 trial of inhaled murepavadin
According to Polyphor, the UK's MHRA has authorized a Phase 1 study of the company's murepavadin inhalation solution, which the company is developing for the treatment of Pseudomonas aeruginosa lung infections in cystic fibrosis patients. Initiation of the study, which is partially funded by the European Innovative Medicines Initiative, is expected within weeks. The … [Read more...] about Polyphor to initiate Phase 1 trial of inhaled murepavadin
Tonix to develop intranasal oxytocin for the treatment of insulin resistance and obesity
Several months after acquiring the rights to TNX-1900 oxytocin nasal spray for the treatment of migraine headaches from Trigemina, Tonix Pharmaceuticals announced that it has acquired an exclusive license to technology from the University of Geneva for the use of oxytocin to treat insulin resistance and related conditions such as obesity. The company has not yet … [Read more...] about Tonix to develop intranasal oxytocin for the treatment of insulin resistance and obesity
Novan selects Catalent for development of intranasal berdazimer sodium
Catalent will supply development services for an intranasal formulation of Novan's berdazimer sodium for COVID-19, the companies said. Berdazimer sodium is a nitric oxide-releasing polymer based on Novan's Nitricil platform, and the company is developing topical gel formulations for the treatment of viral dermatological infections, including molluscum and genital … [Read more...] about Novan selects Catalent for development of intranasal berdazimer sodium
PrEP Biopharm to initiate trial of PrEP-001 intranasal Poly I:C against respiratory viruses
Johnson & Johnson spinout PrEP Biopharm said that it is ready to initiate a real-world trial of its PrEP-001 intranasal "viral RNA surrogate" against common respiratory viruses after the successful completion of a toxicology study in dogs. The trial is designed to evaluate the efficacy PrEP-001, an intranasal dry powder formulation of polyinosinic:polycytidylic … [Read more...] about PrEP Biopharm to initiate trial of PrEP-001 intranasal Poly I:C against respiratory viruses
Phase 1b trial of TFF’s voriconazole DPI in asthma patients is underway
TFF Pharmaceuticals announced that the first subjects have been dosed in a Phase 1b clinical trial of its dry powder voriconazole, which it is developing for the treatment of invasive pulmonary aspergillosis. The trial is expected to enroll 30 adult asthma patients and will evaluate two doses of voriconazole, 40 mg and 80 mg, versus placebo. In September 2020, the … [Read more...] about Phase 1b trial of TFF’s voriconazole DPI in asthma patients is underway
Codagenix and SIIPL initiate Phase 1 trial of COVI-VAC intranasal vaccine
Codagenix and vaccine manufacturer Serum Institute of India (SIIPL) have initiated a Phase 1 trial of COVI-VAC single-dose intranasal, live attenuated vaccine against SARS-CoV-2 after receiving approval from the MHRA, the companies said. Like Codagenix's CodaVax-RSV vaccine, which is also in Phase 1 development, COVI-VAC is based on Codagenix's SAVE codon … [Read more...] about Codagenix and SIIPL initiate Phase 1 trial of COVI-VAC intranasal vaccine
UofL researchers get $8.5 million from US Department of Defense for Q-Griffithsin nasal spray development
The US Department of Defense is providing $8.5 million to fund development of a Q-Griffithsin (Q-GRFT) nasal spray at the University of Louisville, the university said. The funding will support the PREVENT-CoV project for development of a once-daily nasal spray for the prevention of viral infections through a Phase 1 study. Researchers say that because they already … [Read more...] about UofL researchers get $8.5 million from US Department of Defense for Q-Griffithsin nasal spray development